Business strategy

In 2007 Celsion achieved its core strategic goal of becoming a 100% oncology-focused company with multiple products in clinical development. Through the strategic divestiture of its medical device franchise and subsequent restructuring, Celsion has realized a $46 million capital infusion and acquired the talent necessary to ensure success in proprietary drug development. This enabled us to clearly focus on building an integrated oncology enterprise, with the financial resources to substantially complete its pivotal Phase III liver cancer trial, ensuring quality and scalable manufacturing capability and to complete feasibility studies that demonstrate the platform capability of its core heat-sensitive liposomal technology.

The execution of our strategy

Celsion is now funding branded oncology drug development through a fastest-path-to-commercialization strategy for ThermoDox^®, its proprietary thermally sensitive liposomal encapsulation of doxorubicin. We are also identifying opportunities to expand our range of therapeutic indications through investments in our core technology platform.

To maximize global commercialization following approval, Celsion is developing distribution alliance opportunities for ThermoDox in key geographic markets. Once these are finalized we will seek to acquire additional platform technology and chemotherapeutic candidates to add to our development pipeline.

Celsion will continue to strengthen its prospects for the future through its research, license and commercialization agreements with leading institutions, among others: the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic and the North Shore Long Island Jewish Health System.